Interferon Beta

• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results. Neurology 1993; 43:655-661.


• Paty DW, Li DKB, the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. II. MRI analysis. Neurology 1993; 43:662-667.


• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39:285-294.


• Rudick RA, Goodkin DE, Jacobs LD, et al. The impact of interferon beta-1a on neurologic disability in multiple sclerosis. Neurology 1997; 49:358-363.


• Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998; 43:79-87.


• PRISMS Study Group. Randomised, double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. Lancet 1998; 352:1498-1504.


• European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352:1491-1497.


• Cross AH, Antel JP. Antibodies to beta-interferons in multiple sclerosis. Can we neutralize the controversy? Neurology 1998; 50:1206-1208.


• The Once Weekly Interferon for MS Group. Evidence of interferon beta-1a dose response in relapsing remitting MS. The OWIMS study. Neurology 1999; 53:679-686.


• Li DKB, Paty DW, UBC MS/MRI Analysis Research Group, and the PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. Ann Neurol 1999; 46:197-206.


• Miller DH, Molyneux PD, Barker GJ, et al. Effect of interferon beta-1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter randomized double-blind placebo-controlled trial. Ann Neurol 1999; 46:850-859.


• Fischer JS, Priore RL, Jacobs LD et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Ann Neurol 2000; 48: 885-892.


• Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.


• Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Clinical results. Neurology 2001; 56: 1496-1504.


• Li DKB, Zhao GJ, Paty DW et al. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. MRI results. Neurology 2001; 56: 1505-1513.


• The PRISMS Study Group and the University of British Columbia MA/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-1636.


• Freeman JA, Thompson AJ, Fitzpatrick R et al. Interferon beta-1b in the treatment of secondary progressive MS. Impact on quality of life. Neurology 2001; 57: 1870-1875.


• Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582.


• Beck RW, Chandler DL, Cole SR et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002; 51: 481-490.


• Durelli L, Verdun E, Barbero P et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-1460.


• Cohen JA, Cutter GR, Fischer JS et al. Benefit of interferon beta-1a on MSFC progression and quality of life in secondary progressive . Neurology, in press Sept 2002.

• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45:1268-1276.


• Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50:701-708.


• Comi G, Filippi M, Wolinsky JS et al. European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetate on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients with Relapsing Multiple Sclerosis. Ann Neurol 2001; 49: 290-297.

• Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomized placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing remitting multiple sclerosis. Lancet 1997; 349:589-593.


• Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50:1273-1281.


• Lisak RP. Intravenous immunoglobulins in multiple sclerosis. Neurology 1998; 51(Suppl 5):S25-S29.

• Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338:1051-1055.

• Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43:910-918.


• Noseworthy JH, Ebers GC, Gent M, et al. The Canadian Cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337:441-446.

• Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990; 27:591-605.

• Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37:30-40.

• Rice GPA, for the Cladribine Clinical Study Group; and Filippi M and Comi GC, for the Cladribine MRI Study Group. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000; 54:1145-1155.

• Millefiorini E, Gasperini C, Pozzilli C, et al. Randomised placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: A 24-month clinical and MRI outcome. J Neurol 1997; 244:153-159.


• Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62:112-118.

• Noseworthy JH, O'Brien P, Erickson BJ, et al. The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 1998; 51:1342-1352.

• Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878-886. On Acyclovir
  
• Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsing remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Neurol 1996; 243:214-224. On Treatments Under Development.


• Hohlfeld R. Biotechnological agents in the immunotherapy of multiple sclerosis. Brain 1997; 120:865-916.

Keegan M, Pineda A, McClelland RL et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002; 58: 143-146.

• Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsing remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Neurol 1996; 243:214-224.


• Bech E, Lycke J, Gadeberg P et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 2002; 58: 31-36.

• Hohlfeld R. Biotechnological agents in the immunotherapy of multiple sclerosis. Brain 1997; 120:865-916.

• Pozzilli C, Antonini G, Bagnato F et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1b: a randomized trial in multiple sclerosis. J Neurol 2002; 249: 50-56.